Press Release

Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A. is proud to announce its significant collaboration with the Institute of Technology on Immunobiologicals (Bio-Manguinhos/Fiocruz), Brazil's leading public health institute and vaccine manufacturer. This agreement is founded on Bio-Manguinhos’ acquisition of Quantoom's Ntensify™ Midi system in order to produce Brazil’s first proprietary XBB COVID-19 vaccine at Bio-Manguinhos. Discussions are ongoing for the co-development of novel mRNA-based vaccines.

The Ntensify™ Midi is a GMP-grade mRNA production system introducing a novel approach to mRNA synthesis and purification. Its scalable design, construct-agnostic process, and automated production capabilities enable cost-effective, gram-scale batch production of high-quality mRNA as a Drug Substance.

Bio-Manguinhos/Fiocruz, one of Brazil’s largest and globally recognized public laboratories, is renowned for its expertise in vaccine manufacturing. This includes being the world's largest producer of the yellow fever vaccine and the only Latin American laboratory certified by the World Health Organization (WHO) for this purpose. The adoption of the Ntensify™ Midi system at Bio-Manguinhos/Fiocruz marks a significant milestone for Quantoom Biosciences, as it represents the first time a Latin American player builds up GMP mRNA production capabilities. This pivotal industrial validation of Quantoom's innovative technology is further underscored by Bio-Manguinhos' extensive vaccine production capabilities and its esteemed global standing.

The partnership extends beyond equipment acquisition, as Univercells and Bio-Manguinhos/Fiocruz are actively discussing the co-development of novel mRNA-based vaccines, targeting diseases that have a global health impact. Further details will be provided in the near future.

José Castillo, CEO of Quantoom Biosciences and CTO of Univercells, expressed his excitement for this new collaboration: "We are thrilled to see our Ntensify™ Midi system become a cornerstone in Bio-Manguinhos’ vaccine production. This partnership not only validates our technology on an industrial scale but also aligns with our mission to contribute to global health initiatives and equitable vaccine access."

“The partnership with Quantoom and the Ntensify™ Midi system was fundamental to accelerate our development process. We are very excited to get the first batches produced in our GMP area very soon”, celebrates Patricia Neves, Scientific Leader of the RNA Bio-Manguinhos/Fiocruz Project.

About Bio-Manguinhos/Fiocruz

The Institute of Technology in Immunobiologicals (Bio-Manguinhos) is the unit of the Oswaldo Cruz Foundation (Fiocruz) responsible for research, innovation, technological development and the production of vaccines, diagnostic kits and biopharmaceuticals aimed at primarily meeting the demands of national public health. Founded in 1976, Bio-Manguinhos has a prominent presence on the international scene, not only through the export of surplus production to more than 70 countries but also through the exchange of experiences and information, technical-scientific events and partnerships with public and private institutions through Technology Transfer agreements, Partnerships for Productive Development (PDPs) and indigenous development projects, which contribute to expanding its portfolio, which has more than 40 products.

For more information, visit: www.bio.fiocruz.br